2型糖尿病患者与医护人员相比对科兴新冠疫苗的免疫反应及其安全性

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers.

作者信息

Dechates Bothamai, Porntharukchareon Thachanun, Sirisreetreerux Supamas, Therawit Phonthip, Worawitchawong Supanat, Sornsamdang Gaidganok, Soonklang Kamonwan, Tawinprai Kriangkrai

机构信息

Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok 10210, Thailand.

Central Laboratory Center, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok 10210, Thailand.

出版信息

Vaccines (Basel). 2023 Mar 17;11(3):684. doi: 10.3390/vaccines11030684.

DOI:10.3390/vaccines11030684

PMID:36992267

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10052125/

Abstract

BACKGROUND

Vaccines for SARS-CoV-2 have been critical for preventing disease. Previous research showed patients with diabetes have impaired immunity. This study aimed to determine the immunity to coronavirus after CoronaVac by comparing patients with type 2 diabetes (T2D) and healthcare workers (HCW).

MATERIALS AND METHODS

A prospective cohort study evaluated immune responses and safety after two doses of CoronaVac in T2D and HCW groups at Chulabhorn Hospital. The levels of total antibodies against the receptor-binding domain (anti-RBD) of the SARS-CoV-2 spike protein at baseline and 4 weeks after vaccination were collected. The level of anti-RBD concentrations was reported as geometric mean concentration (GMC) and compared between groups using the geometric mean ratio (GMR).

RESULTS

81 participants were included; 27 had T2D and 54 were HCW. After complete vaccination, anti-RBD concentrations were not significantly different between T2D (57.68 binding antibody units (BAU)/mL, 95% confidence interval (CI) = 29.08; 114.44) and HCW (72.49 BAU/mL, 95% CI = 55.77; 94.22) groups. Subgroup analysis showed the GMC of anti-RBD was significantly lower in T2D patients with dyslipidaemia (50.04 BAU/mL) than in T2D patients without dyslipidaemia (341.64 BAU/mL).

CONCLUSIONS

The immune response at 4 weeks after two doses of CoronaVac did not significantly differ between patients with T2D and HCW.

摘要

背景

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗对预防疾病至关重要。先前的研究表明，糖尿病患者免疫力受损。本研究旨在通过比较2型糖尿病（T2D）患者和医护人员（HCW），确定接种科兴新冠疫苗（CoronaVac）后的冠状病毒免疫力。

材料与方法

一项前瞻性队列研究评估了朱拉隆功医院T2D组和HCW组接种两剂科兴新冠疫苗后的免疫反应和安全性。收集了基线时和接种疫苗4周后针对SARS-CoV-2刺突蛋白受体结合域（抗RBD）的总抗体水平。抗RBD浓度水平以几何平均浓度（GMC）报告，并使用几何平均比（GMR）在组间进行比较。

结果

纳入81名参与者；27名患有T2D，54名是医护人员。完全接种疫苗后，T2D组（57.68结合抗体单位（BAU）/mL，95%置信区间（CI）=29.08；114.44）和医护人员组（72.49 BAU/mL，95%CI=55.77；94.22）的抗RBD浓度无显著差异。亚组分析显示，血脂异常的T2D患者的抗RBD GMC（50.04 BAU/mL）显著低于无血脂异常的T2D患者（341.64 BAU/mL）。